Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
T. T. Zhang
R. M. Wang
Z. Yang
G. B. Chen
机构：
[1] The First People’s Hospital of Shangqiu,Department of Oncology
[2] The First People’s Hospital of Shangqiu,Department of General Surgery
[3] The First Affiliated Hospital of Zhengzhou University,Department of Gastrointestinal Surgery
来源：
Clinical and Translational Oncology | 2016年 / 18卷
关键词：
Non-small-cell lung cancer; EGFR-TKIs; Molecular targeted agents; Angiogenesis inhibitors; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 581
页数：5
相关论文
共 50 条
  • [31] Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
    Wang, Fang
    Diao, Xia-Yao
    Zhang, Xiao
    Shao, Qiong
    Feng, Yan-Fen
    An, Xin
    Wang, Hai-Yun
    CANCER COMMUNICATIONS, 2019, 39
  • [32] EGFR-216G/T polymorphism as a predictor of clinical outcomes in advanced non-small cell lung cancer patients treated with EGFR-TKIs: a meta-analysis
    Zhang, Hui-Xian
    Tang, Yang
    Wang, Lu
    Wei, Su-Xian
    Liu, Qing-Xu
    Li, Fang
    Yuan, Xiang-Lin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 10273 - 10280
  • [33] Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non-Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis
    Zhang, Yaxiong
    Kang, Shiyang
    Fang, Wenfeng
    Hong, Shaodong
    Liang, Wenhua
    Yan, Yue
    Qin, Tao
    Tang, Yanna
    Sheng, Jin
    Zhang, Li
    CLINICAL LUNG CANCER, 2015, 16 (02) : 144 - U113
  • [34] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Sheng, Zhixin
    Zhang, Yanxia
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 7
  • [35] EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
    Wu, Jing-Xun
    He, Qi
    Ye, Feng
    Zhou, Qing-Xia
    Chen, Hao-Jun
    Sun, Long
    Wu, Hua
    ONCOTARGETS AND THERAPY, 2018, 11 : 6803 - 6810
  • [36] Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 589 - 599
  • [37] Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
    Petrelli, Fausto
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    CLINICAL LUNG CANCER, 2012, 13 (02) : 107 - 114
  • [38] Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials
    Qi, Wei-Xiang
    Tang, Li-Na
    He, Ai-Na
    Yao, Yang
    Shen, Zan
    RESPIRATORY MEDICINE, 2013, 107 (08) : 1280 - 1283
  • [39] Efficacy and Safety of Vandetanib, a Dual VEGFR and EGFR Inhibitor, in Advanced Non-Small-Cell Lung Cancer: a Systematic Review and Meta-Analysis
    Zhang, Xinji
    Qin, Yingyi
    Li, Hui
    Bai, Chong
    Zhu, Tianyi
    Xu, Jinfang
    Wu, Cheng
    Wu, Mengjie
    Wang, Chaoxiang
    Song, Hualing
    Wei, Lixin
    He, Jia
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (11) : 2857 - 2863
  • [40] Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
    Lu, Yan
    Sun, Chenbing
    Jiao, Lijing
    Liu, Yu
    Gong, Yabin
    Xu, Ling
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345